At UCB, we know we need diverse perspectives and experiences to do our best work. Passionate scientists like Nikita, who exemplify our vision to embrace new knowledge and to work to discover meaningful solutions for patients, are a driving force for innovation at UCB. Stay tuned over the next few weeks to read stories from UCB women researchers who are pushing the boundaries of science. 

• The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
• This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara® (ustekinumab) and Humira® (adalimumab) in achieving skin clearance at week 16

•    Phase II data demonstrated a favorable safety profile across all reported dose groups and clinically meaningful platelet count increases with meaningful decreases in IgG concentration 

UCB is committed to investing in the future generation of leaders. Established in 2017, the UCB Global Regulatory Affairs (GRA) PharmD Fellowship Program, a collaboration with the Industry Pharmacists Organization (IPhO), was designed to provide PharmD graduates with the opportunity to learn and experience all aspects of regulatory affairs under the mentorship of experienced preceptors.

At UCB, we understand our ability to provide impactful solutions patients value begins with our commitment to our employees. As a company, we pride ourselves in the internal resources and programs available to all employees to encourage professional and personal development. We are pleased to introduce a new series here highlighting UCB as an employer. Today we’re shining a spotlight on our internal organization sponsored by Toastmasters International: UCB Speaks.

• Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure (PGTCS) during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period compared with placebo 

33 Winners of the UCB Family Epilepsy Scholarship demonstrate UCB’s commitment to patients.

UCB is committed to the discovery, development, and delivery of differentiated solutions that provide value to patients— improving their lives now and in the future. We’re focused on addressing unmet needs and creating sustainable solutions for patients and society.

Since the beginning of the global COVID-19 crisis, our focus has been on patients, our employees, supporting our communities, as well as the healthcare staff working on the frontlines. 

The COVID-19 pandemic is changing the way we view health care. It

has brought to the forefront of public conversation sobering truths about how social and racial disparities impact the health outcomes of underserved populations in the United States. Often, we attribute an individual’s health solely to the quality of health care they receive when in fact, a host of factors that occur outside clinical walls can play an even greater role in a person’s well-being. Social Determinants of Health (SDH) are the conditions in which people are born, grow, live, work and age, such as socioeconomic factors, housing, physical environment, education, employment, social support and access to health care. SDH can affect a wide range of health outcomes and quality of life, especially for individuals battling chronic illnesses like epilepsy.